1 This paper compares the activity of a range of agonists as stimulants of the fl3-adrenoceptor in rat isolated oesophagus with their ability to afford protection against indomethacin-induced gastric damage in the conscious rat.
Introduction
The existence of atypical JJ-adrenoceptors (also referred to as /33-adrenoceptors) is now well established (Arch & Kaumann, 1993; Howe, 1993) . There are several pharmacological properties which discriminate this form of J-adrenoceptor from others (Blin et al., 1994) , the major factors being resistance to blockade by a range of conventional fl-adrenoceptor antagonists and high potency of a series of novel synthetic agonists Wilson et al., 1984) . The majority of evidence for a functional role of f3-adrenoceptors has been derived from studies in which the effects of these agonists on lipid metabolism have been examined. In rodents, a range of f3-adrenoceptor agonists are potent lipolytic and thermogenic agents Holloway et al., 1989; Bloom et al., 1992) and as a result their therapeutic use as anti-obesity agents is now under evaluation. However, the corresponding role of the P3-adrenoceptor in man is still subject to controversy, although a recent study does suggest that it mediates a lipolytic response in human white fat (Lonnqvist et al., 1993) .
The P3-adrenoceptor is also located within the gastrointestinal tract and isolated preparations taken from several species show that here, it mediates relaxation (reviewed by Arch & Kaumann, 1993) . As a consequence, Bianchetti & Manara (1990) suggested that f3-adrenoceptor agonists may alleviate intestinal hypermotility disorders. We now describe an additional property of,3-adrenoceptor agonists which may be of potential therapeutic use, the ability to confer protection against gastric damage induced by a non-steroidal anti-inflammatory drug (NSAID) . Ulceration was induced in the gastric antrum of the rat as described by Satoh et al. (1981) . This model was chosen because the antrum is the primary site of NSAID-induced damage in man (Roth & Bennett, 1987) . In the current study we have examined the ability of two fadrenoceptor agonists, BRL 37344 and CL 316243 (Bloom et al., 1992) to protect against indomethacin-induced ulceration and compared their profiles with that of the potent and selective f2-adrenoceptor agonist, salmeterol (Ball et al., 1991) and the 1,I-adrenoceptor agonist, denopamine (Nagao et al., 1984) . Before undertaking the in vivo studies, an assessment of the agonists' abilities to stimulate fl-adrenoceptors in isolated tissues was carried out. The following responses were examined: relaxations of rat oesophageal muscularis mucosa and guinea-pig trachea and elevation of guinea-pig atrial rate, which are mediated predominantly, although not exclusively, by P3- (de Boer et al., 1993) , 12-(Carswell & Nahorski, 1983) and P,- (Hedberg et al., 1980) adrenoceptor stimulation, respectively.
Methods

Isolated preparations
Rat oesophageal muscularis mucosae Female Wistar rats (Allen & Hanbury's strain) weighing 100-200 g were killed by stunning and cervical dislocation. The abdomen was opened and the distal 2 cm of oesophagus removed. The muscularis externa was split lengthways and cut away, leaving the inner smooth muscle tube. This was suspended vertically under an initial tension of 0.5 g in modified Krebs-Henseleit solution at 320C and gassed with 95% 02/5% C02. Changes in tension were monitored via an isometric force-displacement transducer (Dynamometer UFI) coupled to an Ormed recorder. The bathing solution was changed 3-4 times and the tissue was then allowed to equilibrate for 30 min before agonists were applied. Throughout the experiment, the Krebs-Henseleit solution contained indomethacin (2.8 gM) to inhibit formation of cyclo-oxygenase products, ascorbate (0.11 mM) to prevent catecholamine oxidation and isobutylmethylxanthine (IBMX (3 pM)) to prolong responses mediated by formation of adenosine 3':5'-cyclic monophosphate (cyclic AMP). In all except the preliminary series of experiments, atenolol (10 gM) and ICI 118551 (1 gM) were also included in the bathing solution to avoid PI-and f2-adrenoceptor activation respectively. Guinea-pig trachea Male Dunkin-Hartley guinea-pigs (350-500 g) were killed by stunning and exsanguination for supply of trachea and right atrium (see below). The trachea was cut into transverse sections, 3-4 cartilage rings wide. Each tracheal ring was then opened by cutting the cartilage opposite the trachealis muscle (Coburn & Tomita, 1973) . The resulting strip preparations were suspended in organ baths via cotton threads tied through the upper and lower cartilages under an initial tension of 1.5 g in bathing solution maintained at 37°C. Two preparations were obtained from each animal. The recording system and equilibration conditions were the same as those described above. In these experiments the Krebs-Henseleit solution contained indomethacin (2.8 gM), ascorbate (0.11 mM), atenolol (10 gM), and atropine (0.4 gM, to prevent muscarinic cholinoceptor activation).
Guinea-pig atrium The right atrium was removed rapidly and mounted for recording of isometric tension in modified Krebs- Animal studies -assessment of the protective effect of fladrenoceptor agonists against gastric ulceration in rats Induction of gastric antral ulceration The method used was largely that described by Satoh et al. (1981) (1 ml 100 g-'). Indomethacin (60 mg kg-', 1 ml 100 g'-body weight) was then injected subcutaneously. Control rats received the subcutaneous injection of indomethacin and oral administration of vehicle (0.5% methyl cellulose in distilled water) for the ,B-adrenoceptor agonist. The animals were then allowed continued access to food but water was withdrawn. In some studies an antagonist was administered p.o. 30 min prior to the P-adrenoceptor stimulant.
Assessment of gastric damage The methods used were those described by Trevethick et al. (1993) . The animals were killed by cervical dislocation 6 h after dosing with indomethacin. The stomachs were removed, opened along the greater curvature and washed in 0.9% saline. An assessment of gastric damage was carried out by an observer who was unaware of the dosing regimen. A transparent plastic grid divided into 1 mm2 sections was placed over the antrum and the area of macroscopic damage assessed as the total area of visible lesions in mm2. This value was then expressed as a percentage of the total antral area. The stomachs were then fixed in 10% (v/v) buffered formalin and tissue sections taken for histological assessment (Trevethick et al., 1993) . Each section was examined for the presence of the following: (i) superficial erosion -damage to surface epithelium only; (ii) deep erosion -glandular epithelium still present; (iii) ulceration -complete loss of the epithelium to the level of the muscularis mucosae.
The length of antral mucosa showing each degree of damage was measured with a calibrated eyepiece scale and calculated as a percentage of the total antral mucosal area.
Analysis of results
All results are expressed as either geometric means with 95% confidence limits or arithmetic means+s.e. mean of n observations. Differences in mean values from isolated tissue experiments were determined by Student's t test; P<0.05 was considered significant. For oesophagus and trachea, responses were expressed as percentage reversal of spasmogen-induced tone. In atria, all responses were expressed as a proportion of the maximal tachycardia induced by isoprenaline. For all preparations the EC50 value refers to the concentration of agonist required to produce half the maximum effect. The potency of an antagonist in the oesophagus was assessed by calculating a concentration ratio (i.e. EC50 value obtained in the presence of antagonist divided by the corresponding control value from another tissue used in the same experiment). When three or more concentrations of antagonist were used, the concentration ratios were pooled to construct a Schild plot, from which a pA2 value was derived. The slope of each Schild plot was shown not to be significantly different from 1 using a t test based on the standard error of the slope estimated from the linear regression. When only a single concentration of antagonist was utilised, an estimate of its pKB value was obtained from the Gaddum equation (Gaddum, 1957) .
In order to compare data from in vivo experiments, an ED50 value (i.e. dose of agonist required to reduce the extent of antral macroscopic damage by 50%) was calculated for each fladrenoceptor stimulant. Statistical comparisons were performed with the Mann-Whitney U test. A P value <0.05 was considered statistically signficant.
Compounds
The following compounds were used: ascorbic acid, carbachol (BDH), atenolol, atropine hydrochloride, 5-hydroxytryptamine creatinine sulphate (5-HT), indomethacin, 3-isobutyl-l-methyl-xanthine, isoprenaline hemisulphate, propranolol hydrochloride (Sigma), Table 2 ). However, the corresponding values when salmeterol was the relaxant were <6.5 for cyanopindolol and <5.5 for propranolol, which suggests that this response was not mediated via ,B-adreno- The EC50 values are geometric means with 95% confidence limits of n observations. The potency ratio is derived from the mean EC50
value for each compound. (Figure 4 ). The effect of cyanopindolol on the gastroprotective response was not evaluated in these studies because preliminary experiments showed that it markedly exacerbated the degree of antral damage produced by indomethacin. 
Discussion
The results of this study show that P-adrenoceptor agonists inhibit indomethacin-induced gastric antral ulceration in rats.
The use of subtype-selective agonists suggests that both f2-and f3-adrenoceptors are involved in this gastroprotective response. In contrast, we have no evidence to suggest an involvement of f,-adrenoceptors, as denopamine, a selective fIadrenoceptor agonist, did not inhibit ulceration at doses up to 10 mg kg-', p.o. which is a 13 fold higher dose than that required to produce a 50% increase in cardiac contractility in conscious rats (Yabana et al., 1986) .
The finding that the 132-adrenoceptor selective agonist salmeterol, is gastroprotective is not surprising, as similar results have been obtained with salbutamol (Fielding et al., 1975; Espluges et al., 1982) . Isoprenaline has also been shown to afford protection against ethanol-induced gastric damage via stimulation of #2-adrenoceptors (Howard et al., 1993) . The mechanisms by which this protective effect may be mediated are discussed in detail elsewhere (Esplugues et al., 1982) , and will not be reviewed here, as a fJ2-adrenoceptor agonist was included in the current study for comparative purposes only. The key result from the present series of experiments was the demonstration that CL 316243 and BRL 37344 inhibited indomethacin-induced gastric ulceration in the rat. The results from the pharmacological characterization carried out on isolated tissues show that both are potent P3-adrenoceptor agonists, as judged by their ability to relax rat oesophagus muscularis mucosae, a preparation in which this response is mediated predominantly, if not exclusively, via f3-adrenoceptors (De Boer et al., 1993) . Furthermore, the relaxation was resistant to blockade by a combination of atenolol and ICI 118551 at concentrations at least 100 fold higher than those required to block PI-and f32-adrenoceptors respectively.
In contrast, the relaxant responses to isoprenaline and CL 316243 were blocked in a competitive manner by cyanopindolol and were also antagonized by high concentrations of propranolol. Overall, this pharmacological profile is consistent with that of the fl3-adrenoceptor. However, our pA2 values for cyanopindolol and propranolol are both higher (by 0.5-1.0 log unit) than those obtained on oesophagus by Ford et al. (1992) . The reason for this is unknown, but the values that we quote are consistent with those which we obtain on other gastrointestinal preparations containing f,3-adrenoceptors (unpublished observations). Overall, in keeping with previous literature reports, Bloom et al., 1992) (reverse hatched columns) and 10 (solid columns) mgkg-1 (p.o.). Significant differences *(P<0.05 and **P<0.01; Mann-Whitney U test) between the group treated with agonist alone and that receiving agonist plus antagonist (n =5-10 rats for each group).
mation in the gastric antrum, which suggests that it is not the absence of protective prostalandins per se which is responsible for the ulcerogenic stimulus. Mersereau & Hinchey (1988) demonstrated that indomethacin markedly enhanced basal myoelectrical activity of rat gastric smooth muscle. They proposed that this altered smooth muscle state, in combination with the inhibition of prostaglandin synthesis, renders the mucosa vulnerable to injury by increased peristaltic action. The fl3-adrenoceptor agonists have relaxant effects in a range of isolated preparations taken from the GI tract of various species (reviewed by Arch & Kaumann, 1993) . Furthermore, studies using /33-adrenoceptor agonists developed by Sanofi have shown that these compounds inhibit colonic myoelectric activity in both the anaesthetized (Giudice et al., 1989) and conscious (Croci et al., 1991) rat. Thus it is likely that this inhibitory effect contributes in some way to the gastroprotective effect of ,63-adrenoceptor agonists. However, exactly how this occurs is at present unclear, although it is of interest that Livingston et al. (1993) have shown that an increase in peristaltic activity (by field stimulation) of rat stomach leads to a reduction in blood flow which is particularly profound in the antral area. Thus it is possible that the #3-adrenoceptor agonists confer protection in two ways: (i) by directly inhibiting the elevated level of contractile activity of gastric smooth muscle induced by indomethacin; (ii) by reversing the reduction in blood flow caused by this hypermotile state.
In conclusion, we have demonstrated that both 2-and 3-adrenoceptor agonists are capable of preventing gastric damage induced by indomethacin in the rat. Assessment of the therapeutic potential of this class of compounds as gastroprotective agents in man awaits the development of an agonist that is potent at the human fl3-adrenoceptor. 
